Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (21-30 of 353) with videos related to

Pageof 36
Sort By:
Cleveland Clinic Journal of Medicine|November 24, 2020
In Reply: Assessing stable coronaryartery diseaseVinayak Nagaraja, A Michael Lincoff
European Heart Journal. Cardiovascular Pharmacotherapy|December 9, 2023
The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular diseaseA Michael Lincoff, Donna H Ryan
Current Opinion in Cardiology|June 9, 2007
The role of clopidogrel in the management of ischemic heart diseaseJohn M Galla, A Michael Lincoff
Cleveland Clinic Journal of Medicine|December 3, 2009
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding riskLawrence D Lazar, A Michael Lincoff
Cleveland Clinic Journal of Medicine|July 12, 2002
GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary ArteriesArman T Askari, A Michael Lincoff
Cleveland Clinic Journal of Medicine|May 3, 2020
Aspirin for primary prevention of atherosclerotic cardiovascular eventsAldo L Schenone, A Michael Lincoff
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 27, 2010
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitusMatthew A Cavender, A Michael Lincoff
Expert Opinion on Drug Safety|September 7, 2012
Safety profile and bleeding risk of ticagrelor compared with clopidogrelChristopher H May, A Michael Lincoff
Cleveland Clinic Journal of Medicine|August 2, 2020
In Reply: Aspirin for primary preventionAldo L Schenone, A Michael Lincoff
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 3, 2008
Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomesKellan E Ashley, A Michael Lincoff
Pageof 36

Showing results (21-30 of 353) with videos related to

Sort By:
Pageof 36
Cleveland Clinic Journal of Medicine|November 24, 2020
In Reply: Assessing stable coronaryartery diseaseVinayak Nagaraja, A Michael Lincoff
European Heart Journal. Cardiovascular Pharmacotherapy|December 9, 2023
The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular diseaseA Michael Lincoff, Donna H Ryan
Current Opinion in Cardiology|June 9, 2007
The role of clopidogrel in the management of ischemic heart diseaseJohn M Galla, A Michael Lincoff
Cleveland Clinic Journal of Medicine|December 3, 2009
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding riskLawrence D Lazar, A Michael Lincoff
Cleveland Clinic Journal of Medicine|July 12, 2002
GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary ArteriesArman T Askari, A Michael Lincoff
Cleveland Clinic Journal of Medicine|May 3, 2020
Aspirin for primary prevention of atherosclerotic cardiovascular eventsAldo L Schenone, A Michael Lincoff
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 27, 2010
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitusMatthew A Cavender, A Michael Lincoff
Expert Opinion on Drug Safety|September 7, 2012
Safety profile and bleeding risk of ticagrelor compared with clopidogrelChristopher H May, A Michael Lincoff
Cleveland Clinic Journal of Medicine|August 2, 2020
In Reply: Aspirin for primary preventionAldo L Schenone, A Michael Lincoff
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 3, 2008
Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomesKellan E Ashley, A Michael Lincoff
Pageof 36